1255909-03-5
Chemical Structure
Mufemilast
Synonym(s): Hemay005
- CAS No.: 1255909-03-5
- Formula:C20H22N2O7S2
- Molecular Weight:466.53
IUPAC Name: pyrrolidine-2-carboxylic-2,3,3,4,4,5,5-d7 acid
InChIKey: PRSNGWLHNWGOKD-CQSZACIVSA-N
SMILES: O=C1C2=C(NC(C)=O)SC=C2C(N1[C@@H](C3=CC(OCC)=C(C=C3)OC)CS(C)(=O)=O)=O
Biological Activity: Mufemilast (Heymay005) is a selective and orally active phosphodiesterase 4 (PDE4) inhibitor (IC50 = 80-120 nM). Mufemilast modulates cytokines upregulated in Behςet’s syndrome (BS). Mufemilast displays a significant inhibitory effect on TNF-α, which is an important proinflammatory cytokine target in the disease process of psoriasis. Mufemilast can be studied in research for diseases such as rheumatoid arthritis, psoriasis and BS[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Mufemilast | 99.35% | Mufemilast (Heymay005) is a selective and orally active phosphodiesterase 4 (PDE4) inhibitor (IC50 = 80-120 nM). Mufemilast modulates cytokines upregulated in Behςet’s syndrome (BS). Mufemilast displays a significant inhibitory effect on TNF-α, which is an important proinflammatory cytokine target in the disease process of psoriasis. Mufemilast can be studied in research for diseases such as rheumatoid arthritis, psoriasis and BS. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Liu Tian, et al., Efficacy and Safety of Mufemilast in Patients with Behçet's Syndrome: A Phase 2, Double-Blind, Placebo-Controlled Trial.
- [2]. Yilmaz, O., et al., (2024). New and emerging oral therapies for psoriasis. Drugs in context, 13, 2024-5-6. [Content Brief]
- [3]. Peng, T., et al., (2020). Advances in the Development of Phosphodiesterase-4 Inhibitors. Journal of medicinal chemistry, 63(19), 10594–10617. [Content Brief]
- [4]. Liu, X., et al., (2018). Determination of a PDE4 inhibitor Hemay005 in human plasma and urine by UPLC-MS/MS and its application to a PK study. Bioanalysis, 10(11), 863–875. [Content Brief]
Keywords
